These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25603042)

  • 61. Off-label use of medical devices in radiology: regulatory standards and recent developments.
    Smith JJ
    J Am Coll Radiol; 2010; 7(2):115-9. PubMed ID: 20142085
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prescription drug products; patient package insert requirements--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(1):28-30. PubMed ID: 10324121
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Stem-cell therapy takes off in Texas.
    Cyranoski D
    Nature; 2012 Feb; 483(7387):13-4. PubMed ID: 22382952
    [No Abstract]   [Full Text] [Related]  

  • 64. FDA weighs policing electronic patient record.
    Hosp Case Manag; 1997 May; 5(5):81-3. PubMed ID: 10167258
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Stem cells, cloning, and regulation.
    Guenin LM
    Mayo Clin Proc; 2005 Feb; 80(2):241-50. PubMed ID: 15704779
    [No Abstract]   [Full Text] [Related]  

  • 66. Efficacy considerations for U.S. Food and Drug Administration approval of diagnostic radiopharmaceuticals.
    Gorovets A; Marzella L; Rieves D; Yang L
    J Nucl Med; 2013 Aug; 54(8):1479-84. PubMed ID: 23749997
    [TBL] [Abstract][Full Text] [Related]  

  • 67. FDA overview and current challenges in regulation of human subject protection. Food and Drug Administration.
    Nightingale SL
    J Int Assoc Physicians AIDS Care; 1997 Jan; 3(1):24-6. PubMed ID: 11363959
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Current FDA directives for promoting public health.
    Hayes AH
    Am J Hosp Pharm; 1982 Mar; 39(3):427-31. PubMed ID: 7072727
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: part II--a method of software documentary analysis.
    Ilic N; Savic S; Siegel E; Atkinson K; Tasic L
    Stem Cells Transl Med; 2012 Dec; 1(12):909-20. PubMed ID: 23283552
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bringing smart pills to market: FDA regulation of ingestible drug/device combination products.
    Avery M; Liu D
    Food Drug Law J; 2011; 66(3):329-52, i. PubMed ID: 24505852
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Regulating (for the benefit of) future persons: a different perspective on the FDA's jurisdiction to regulate human reproductive cloning.
    Javitt GH; Hudson K
    Utah Law Rev; 2003; 2003(4):1201-29. PubMed ID: 15622618
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Regulatory Requirements for PET Drug Production.
    Schwarz SW; Dick D; VanBrocklin HF; Hoffman JM
    J Nucl Med; 2014 Jul; 55(7):1132-7. PubMed ID: 24914057
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Product regulation and the clinical translation of stem cell research.
    von Tigerstrom B
    Stem Cell Rev Rep; 2009 Jun; 5(2):135-9. PubMed ID: 19259831
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The role of the FDA in the effort against AIDS.
    Young FE
    Public Health Rep; 1988; 103(3):242-5. PubMed ID: 3131814
    [TBL] [Abstract][Full Text] [Related]  

  • 75. US stem cell clinics, patient safety, and the FDA.
    Turner L
    Trends Mol Med; 2015 May; 21(5):271-3. PubMed ID: 25945404
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mapping and driving the stem cell ecosystem.
    Knoepfler PS
    Regen Med; 2018 Oct; 13(7):845-858. PubMed ID: 30289055
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Texas H.B. 810: Increased Access to Stem Cell Interventions or an Increase in Unproven Treatments?
    Matthews K; Kunisetty B; Sprung K
    Stem Cells Dev; 2018 Nov; 27(21):1463-1465. PubMed ID: 30122128
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: part I--a method of manual documentary analysis.
    Ilic N; Savic S; Siegel E; Atkinson K; Tasic L
    Stem Cells Transl Med; 2012 Dec; 1(12):898-908. PubMed ID: 23283551
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Stem cell therapy in sports medicine: current applications, challenges and future perspectives.
    Palermi S; Gnasso R; Belviso I; Iommazzo I; Vecchiato M; Marchini A; Corsini A; Vittadini F; Demeco A; De Luca M; Tarantino D; Romano V; Sacco A; Sirico F
    J Basic Clin Physiol Pharmacol; 2023 Nov; 34(6):699-706. PubMed ID: 37682309
    [TBL] [Abstract][Full Text] [Related]  

  • 80. US Food and Drug Administration Perspectives on Clinical Mass Spectrometry.
    Lathrop JT; Jeffery DA; Shea YR; Scholl PF; Chan MM
    Clin Chem; 2016 Jan; 62(1):41-7. PubMed ID: 26553791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.